| Title |
Nanomedicines: From Bench to Bedside and Beyond
|
|---|---|
| Published in |
The AAPS Journal, August 2016
|
| DOI | 10.1208/s12248-016-9961-7 |
| Pubmed ID | |
| Authors |
Henry Havel, Gregory Finch, Pamela Strode, Marc Wolfgang, Stephen Zale, Iulian Bobe, Hagop Youssoufian, Matthew Peterson, Maggie Liu |
| Abstract |
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements-only together can they realize the full potential of nanomedicines for patients. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| Canada | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 159 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| India | 1 | <1% |
| Ireland | 1 | <1% |
| Belgium | 1 | <1% |
| Unknown | 156 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 34 | 21% |
| Student > Master | 20 | 13% |
| Researcher | 19 | 12% |
| Student > Bachelor | 15 | 9% |
| Other | 8 | 5% |
| Other | 23 | 14% |
| Unknown | 40 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 40 | 25% |
| Biochemistry, Genetics and Molecular Biology | 17 | 11% |
| Chemistry | 15 | 9% |
| Medicine and Dentistry | 13 | 8% |
| Agricultural and Biological Sciences | 7 | 4% |
| Other | 22 | 14% |
| Unknown | 45 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 September 2016.
All research outputs
#14,208,077
of 22,884,315 outputs
Outputs from The AAPS Journal
#782
of 1,288 outputs
Outputs of similar age
#214,346
of 366,375 outputs
Outputs of similar age from The AAPS Journal
#20
of 37 outputs
Altmetric has tracked 22,884,315 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,288 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 366,375 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.